Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

That depends upon the back end including any benchmark payments and royalties. For example, a partnership for the entire anti-inflammatory and antibiotic platform might include milestone payments for each indication from ABX to the entire GI track plus OM, and dermatitis, etc. It’s a huge expanse of separate indications. In fact, each general application can be considered a separate platform. Again for example, a partner might simply want the IBD platform. On top of a large upfront payment and milestones for UP, there would additional milestones for development of each of the formulations that reach other IBD disease areas. The license and structure of the agreement might take the SP to $20, but there would still be 3 other known platforms for development on the table. Plus, full monetization for IBD would still be in it’s early stages due to significant royalties.